Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension

BACKGROUND: Young children with congenital adrenal hyperplasia (CAH) require small doses (0.1-1.25 mg) of hydrocortisone (HC) to control excess androgen production and avoid the negative effects of overtreatment. The smallest commercially available HC formulation, before the recent US Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rayess, Heba, Addo, O Yaw, Palzer, Elise, Jaber, Mu’taz, Fleissner, Kristin, Hodges, James, Brundage, Richard, Miller, Bradley S, Sarafoglou, Kyriakie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758402/
https://www.ncbi.nlm.nih.gov/pubmed/35047717
http://dx.doi.org/10.1210/jendso/bvab193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758402/
https://www.ncbi.nlm.nih.gov/pubmed/35047717
http://dx.doi.org/10.1210/jendso/bvab193

Ejemplares similares